To determine whether oral administration of the antifungal fluconazole during the entire period of treatment of bacterial peritonitis ( BP ) , exit-site infection ( ESI ) , or tunnel infection ( TI ) prevents later appearance of fungal peritonitis ( called secondary ) in patients with chronic kidney disease stage 5 in a peritoneal dialysis ( PD ) program .
